Skip to content

MDMA research published in 2011

Page 6 of 7: studies 101 to 120 of 125, newest first. Back to the MDMA overview

Studies

Hysteria Complicated by Ecstasy: The Case of Nanette Leroux (review)

Bulletin of the history of medicine March 1, 2011 Toby Gelfand

Reviewed by: Hysteria Complicated by Ecstasy: The Case of Nanette Leroux Toby Gelfand Jan Goldstein . Hysteria Complicated by Ecstasy: The Case of Nanette Leroux. Princeton, N.J.: Princeton University Press, 2010. xi + 246 pp. Ill. $29.95 (978-0-691-01186-8). Nanette Leroux, an eighteen-year-old French peasant girl, fell gravely ill in the summer of 1822 with a bewildering array of nervous...

Age of Sexual Initiation, Psychiatric Symptoms, and Sexual Risk Behavior among Ecstasy and LSD Users in Porto Alegre, Brazil: A Preliminary Analysis.

Journal of Drug Issues March 1, 2011 Flávio Pechansky, Lysa Remy, Hilary L. Surratt et al.

Ecstasy and LSD use is widespread in large Brazilian cities, but there is limited information on their use among young, middle-class, club goers in Brazil. We conducted standardized face-to-face interviews with 200 male and female ecstasy and/or LSD users, focusing on drug use and sexual history, current risk behaviors, and psychiatric symptomatology. Participants with early sexual debut...

Paul in Ecstasy: The Neurobiology of the Apostle’s Life and Thought (review)

Toronto Journal of Theology March 1, 2011 Dietmar Neufeld

Reviewed by: Paul in Ecstasy: The Neurobiology of the Apostle’s Life and Thought Dietmar Neufeld Colleen Shantz . Paul in Ecstasy: The Neurobiology of the Apostle’s Life and Thought. Cambridge: Cambridge University Press, 2009. Pp. v + 267. Cloth, US$64.00. ISBN 978-0-521-86610-1. In a provocative, long-overdue correction of a primarily cognicentric approach to Paul, Shantz charts a finely...

Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA ('Ecstasy'): an 18F-dopa PET study.

Neuropsychopharmacology March 2011 Yen F Tai, Rosa Hoshi, Catherine M Brignell et al.

Ecstasy (±3,4-methylenedioxymethamphetamine, MDMA) is a popular recreational drug with known serotonergic neurotoxicity. Its long-term effects on dopaminergic function are less certain. Studying the long-term effects of ecstasy is often confounded by concomitant polydrug use and the short duration of abstinence. We used (18)F-dopa positron emission tomography (PET) to investigate the long-term...

Methylone and Monoamine Transporters: Correlation with Toxicity

Current Neuropharmacology March 1, 2011 Chiharu Sogawa, Norio Sogawa, Kazumi Ohyama et al. 50 citations

Methylone (2-methylamino-1-[3,4-methylenedioxyphenyl]propane-1-one) is a synthetic hallucinogenic amphetamine analog, like MDMA (3,4-methylenedioxy- methamphetamine), considered to act on monoaminergic systems. However, the psychopharmacological profile of its cytotoxicity as a consequence of monoaminergic deficits remains unclear. We examined here the effects of methylone on the transporters...

The Nature of 3, 4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonergic Dysfunction: Evidence for and Against the Neurodegeneration Hypothesis

Current Neuropharmacology March 1, 2011 Dominik K. Biezonski, Jerrold S. Meyer 51 citations

High doses of the recreational drug 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") have been well-documented to reduce the expression of serotonergic markers in several forebrain regions of rats and nonhuman primates. Neuroimaging studies further suggest that at least one of these markers, the plasma membrane serotonin transporter (SERT), may also be reduced in heavy Ecstasy users. Such...

Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice Lacking Dopamine and/or Serotonin Transporters

Current Neuropharmacology March 1, 2011 Yoko Hagino, Yukio Takamatsu, Hideko Yamamoto et al. 64 citations

3,4-Methylendioxymethamphetamine (MDMA) has both stimulatory and hallucinogenic properties which make its psychoactive effects unique and different from those of typical psychostimulant and hallucinogenic agents. The present study investigated the effects of MDMA on extracellular dopamine (DA(ex)) and serotonin (5-HT(ex)) levels in the striatum and prefrontal cortex (PFC) using in vivo...

DOI: 10.2174/157015911795017254 (opens in new tab) MDMA Serotonin transporter Dopamine transporter Pharmacology +2

Pill content, dose and resulting plasma concentrations of 3,4‐methylendioxymethamphetamine (MDMA) in recreational ‘ecstasy’ users

Addiction February 14, 2011 Kate Morefield, Michael Keane, Peter Felgate et al. 83 citations

ABSTRACT Aims To improve our understanding of the pharmacology of ‘ecstasy’ in recreational environments; in particular, to describe the composition of ecstasy pills, patterns of ecstasy use and the relationship between dose of 3,4‐methylendioxymethamphetamine (MDMA) and resulting plasma concentrations. Design, setting and participants A naturalistic observational study of 56 experienced...

Serotonin 5-HT4 receptors in the nucleus accumbens are specifically involved in the appetite suppressant and not locomotor stimulant effects of MDMA ('ecstasy').

Psychopharmacology February 2011 H M Francis, N J Kraushaar, L R Hunt et al.

3,4-Methylenedioxymethamphetamine (MDMA) abuse is a substantial problem in young adults. Due to a high focus on body image in this population, two main factors that may encourage MDMA use are the appetite suppressant and locomotor stimulant effects of this drug. The nucleus accumbens (NAc) is a brain region associated with the regulation of motivated and locomotor behaviours, and recent...

Acute effects of MDMA (3,4-methylenedioxymethamphetamine) on EEG oscillations: alone and in combination with ethanol or THC (delta-9-tetrahydrocannabinol).

Psychopharmacology February 2011 Marieke M Lansbergen, Glenn Dumont, Joop van Gerven et al.

Typical users of 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") are polydrug users, combining MDMA with alcohol or cannabis [most active compound: delta-9-tetrahydrocannabinol (THC)]. The aim of the present study was to investigate whether co-administration of alcohol or THC with MDMA differentially affects ongoing electroencephalogram (EEG) oscillations compared to the administration of...

Ultrastructural characterization of tryptophan hydroxylase 2-specific cortical serotonergic fibers and dorsal raphe neuronal cell bodies after MDMA treatment in rat.

Psychopharmacology February 2011 Csaba Ádori, Péter Low, Rómeó D. Andó et al.

3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") is a widely used recreational drug known to cause selective long-term serotonergic damage. The aim of this study was to characterize the ultrastructure of serotonergic pericarya and proximal neurites in the dorsal raphe nucleus as well as the ultrastructure of serotonergic axons in the frontal cortex of adolescent Dark Agouti rats 3 days after...

Regulation of opioid gene expression in the rat brainstem by 3,4-methylenedioxymethamphetamine (MDMA): role of serotonin and involvement of CREB and ERK cascade.

Naunyn-Schmiedeberg's Archives of Pharmacology February 2011 Manuela Di Benedetto, Sussy del Carmen Bastías Candia, Claudio D'Addario et al.

The amphetamine analogue 3,4-methylendioxymetamphetamine (MDMA, Ecstasy) causes complex adaptations at the molecular and cellular levels altering the activity of different brain neurotransmitters. The present study aims to verify the effects of single and repeated injections of MDMA on dynorphin and nociceptin systems gene regulation in the brainstem, an area rich in neurons containing...

The A2a adenosine receptor modulates the reinforcement efficacy and neurotoxicity of MDMA

Journal of Psychopharmacology January 24, 2011 Jéssica Ruiz‐medina, Catherine Ledent, Olga Carretón et al. 33 citations

Adenosine is an endogenous purine nucleoside that plays a neuromodulatory role in the central nervous system. A2a adenosine receptors have been involved in reward-related processes, inflammatory phenomena and neurotoxicity reactions. In the present study, we investigated the role of A2a adenosine receptors on the acute pharmacological effects, reinforcement and neuroinflammation induced by MDMA...

DOI: 10.1177/0269881110389210 (opens in new tab) MDMA Neurotoxicity Adenosine a2a receptor Pharmacology +6

The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’), methamphetamine and d-amphetamine

Biological Chemistry January 2, 2011 Thomas Steinkellner, Michael Freissmuth, Harald H. Sitte et al. 112 citations

Abstract Amphetamine (‘Speed’), methamphetamine (‘Ice’) and its congener 3,4-methylenedioxymethamphetamine (MDMA; ‘Ecstasy’) are illicit drugs abused worldwide for their euphoric and stimulant effects. Despite compelling evidence for chronic MDMA neurotoxicity in animal models, the physiological consequences of such toxicity in humans remain unclear. In addition, distinct differences in the...

Increased oxidative-modifications of cytosolic proteins in 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-exposed rat liver.

PROTEOMICS January 2011 Vijay Upreti, Kwan–hoon Moon, Li‐rong Yu et al.

It is well established that 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) causes acute liver damage in animals and humans. The aim of this study was to identify and characterize oxidative modification and inactivation of cytosolic proteins in MDMA-exposed rats. Markedly increased levels of oxidized and nitrated cytosolic proteins were detected 12 h after the second administration of two...

Neuroadaptive Changes in 5-HT1A Autoreceptor Sensitivity Following High-Dose MDMA Treatment

2011 Simon David Fisher

Rationale: There is evidence that the serotonin (5-HT) deficits and related cognitive and mood impairments caused by +/-3,4- methylenedioxymethamphetamine (MDMA) may be mediated by neuroadaptations of the 5-HT1A autoreceptor. Objectives: The increase in sensitivity of the 5-HT1A autoreceptor caused by highdose, repeated MDMA treatment was assessed neurochemically, by measuring 5- HTP...